Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04061980
Title Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors OHSU Knight Cancer Institute
Indications

thyroid gland cancer

Therapies

Binimetinib + Encorafenib

Binimetinib + Encorafenib + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Providence Portland Medical Center Recruiting Portland Oregon 97213 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field